Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT-747 (OCA) Monotherapy in Primary Biliary Cirrhosis
NCT00570765Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jan 2008
- Primary completion
- Sep 2010
- Modality
- Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 2 trial of obeticholic acid in primary biliary cholangitis (PBC), sponsored by Intercept Pharmaceuticals. Started Jan 2008; status: completed.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT00570765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570765.